Partnering

Creating value together

We are tirelessly dedicated to restoring brain health for people living with psychiatric and neurological diseases. From early-stage science to commercialization, partnerships are a key pillar in our strategy and in our ambition to become leaders within brain health.

Why partner with Lundbeck

Successful partnerships, from early-stage science to commercialization, have been one of the main drivers in establishing Lundbeck’s current position in brain science. 

 

Lundbeck is globally recognized as one of the leading companies within neurological and psychiatric disorders and is one of the only fully integrated pharmaceutical companies focused solely within brain diseases. Restoring brain health requires a concerted effort, and we are committed to developing new and better treatment options from innovations born in house and externally.

 

Lundbeck’s long experience and continuous work within brain diseases have provided us with a strong global network in preclinical and clinical neuroscience research. Partnering with external specialists in their respective fields of brain disease is a cornerstone of our strategy, and we always strive to be the partner of choice. Lundbeck holds the knowledge, capabilities and financial stability to spur innovation, both through our internal laboratories and external partners.

 

We enter into partnerships recognizing that your business strengths are different and complementary to our own. This is why we customize each partnership to ensure value creation and to translate today’s know-how into tomorrow’s advancements in life-changing therapies.

Areas of interest

We actively seek access to external innovation, particularly where we see best-in-class opportunities to develop transformative medicines, and where we can leverage our own global drug development and commercial expertise to bring new medicines to patients.

 

Our primary ambition is to find innovative projects and products that will advance neuroscience and develop novel and innovative treatments for patients. By combining our internal R&D capabilities with external alliances, we significantly broaden the opportunities to achieve our end goal. Opportunities in scope include:

 

  • Discovery technology platforms
  • Enabling technologies, such as biomarkers and imaging
  • Digital platforms, such as wearables
  • Discovery projects
  • Pre-clinical projects
  • Early and mid-stage developments projects
  • Regional and global commercialized products

Global business development and strategy

Global business development and strategy consists of two teams

Search and assessment

 

  • Responsible for Lundbeck’s external innovation strategy
  • Focused on early-stage opportunities and continuously scouting and screening opportunities

 

Transactions & Alliance management

 

  • Focused on later stage opportunities
  • Responsible for outlicensing
  • Negotiation and contracting
  • Valuations
  • Alliance management for all partnerships

Our partnering process

We have a rigorous process to screen, assess, and execute on external  opportunities ranging from technologies, pipeline assets, and company acquisitions. We use a tried-and-tested cross-functional approach to conduct an effective in-depth evaluation of every business development opportunity.

 

Our team works closely with internal stakeholders and subject matter experts to ensure an agile exchange, knowledge sharing and fast decision making.

 

In this way, we aim to create the strongest possible foundation for a mutual understanding of how to shape the market for tomorrow.

 

Our established business development process has four key stages:

  • Initial scientific evaluation
  • Identifying each candidate as a potential partnering opportunity
  • Evaluation of business hypothesis
  • Entry into a CDA (confidential disclosure agreement)

  • In-depth internal evaluation of confidential material to confirm scientific rationale
  • In-depth internal commercial assessment of business rationale
  • Initial business case development
  • Development of non-binding terms

  • Completion of due diligence
  • External validation of business rationale, including market research, and exclusivity assessment
  • Confirmation of business case

  • Negotiating deal terms and conditions
  • Finalizing deal terms and conditions
  • Finalizing contract

   

Current partnerships & Alliance management

The treatments we have launched over the last 10 years demonstrate Lundbeck’s ability and commitment to establishing exceptional partnerships. We collaborate with companies, academic institutions, individuals, and third parties from round the world. Lundbeck has around 80-100 scientific and commercial partnerships and collaborations.

Some of our key collaborators are

 

  • Otsuka
  • Takeda
  • AprilBio
  • R-genta
  • Teva
  • Mochida
  • Dainippon Sumitomo
  • Denovo
  • Nhwa Pharmaceutials
  • Merz

 

Key acquisitions by Lundbeck

 

  • Ovation (2009)
  • Chelsea Therapeutics (2014)
  • Prexton (2018)
  • Abide Therapeutics (2019)
  • Alder Biopharmaceuticals (2019)
  • Longboard Pharmaceuticals (2024)
Once we have entered into a partnership, our Alliance Management Team takes the lead on laying the foundation for a well-functioning relationship with the key purpose of creating value for the partnership as a whole and to satisfy the strategic needs for both partners.

Explore partnering opportunities

More from Lundbeck